Allogeneic stem cell transplantation (SCT) is one of the most expensive medical procedures. However, only a few studies to date have addressed the costs of HLAidentical sibling transplantation and only one study has reported costs of unrelated transplantation. No recent cost analysis with a proper follow-up period and donor identification expenses is available on related or voluntary matched unrelated donor (MUD) SCT for adult AML or ALL. Therefore, we calculated direct medical (hospital) costs based on 97 adults who underwent HLA-identical sibling bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT), and patients who received a graft from a MUD between 1994 and 1999. The average costs per transplanted patient were 98 334 (BMT), 151 754 (MUD), and 98 977 (PBSCT), including donor identification expenses, 2 years follow-up and costs of patients who were not transplanted after they had been planned to receive an allograft. The majority of these costs was generated during the hospitalisation for graft infusion. For MUD transplants, nearly one-third of these costs was spent on the search for a suitable donor. For patients who were alive after 2 years, cumulative expenses were calculated to be 103 509 (BMT), 173 587 (MUD), and 105 906 (PBSCT).
Allogeneic SCT for leukaemias is known to be one of the most expensive medical procedures, due to long hospital care, high-technology medical interventions and the provision of specialised facilities. 1 In The Netherlands, a few licensed hospitals perform allogeneic stem cell transplantations (SCT), for which they receive historically determined financial budgets. However, these budgets were assigned more than 10 years ago and are currently assumed to be far from sufficient. Due to new developments such as use of grafts from unrelated voluntary donors, improved possibilities of preventing and treating graft-versus-host disease, and use of donor lymphocyte infusions, a revision of the costs of SCT was felt to be needed to allow adequate budget allocation.
Few studies have addressed the costs of SCT. 2 To our knowledge, only one study on costs of transplantations using unrelated donor stem cells has been published, for patients with chronic phase chronic myelogenous leukaemia. 3 Published studies on the basis of real patient data estimating costs of SCT for adult leukaemia using HLAidentical sibling donors show wide variations and range from approximately US$ 20 000 to US$ 225 000. [4] [5] [6] [7] [8] [9] The differences are probably due to different costing methodologies and varying follow-up durations. These also hamper valid comparison of results. Except for the studies of Lee et al 3 and Faucher et al, 9 most studies are based on data from patients treated before 1990. Unfortunately, the Lee study 3 only considered chronic phase chronic myeloid leukaemia and the Faucher study 9 only considered a 100-day follow-up and did not include donor identification costs. Analysing cost data from recently treated acute leukaemia patients is recommended, because learning curve effects of this kind of highly specialised care could have reduced the costs of SCT. 2 Bennett et al 10 demonstrated such an effect on the costs of autologous SCT for Hodgkin's disease and non-Hodgkin's lymphoma.
To present recent costs of SCT for adult patients with acute leukaemia and to provide a basis for revision of hos-Bone Marrow Transplantation pital budgets, we calculated direct medical (hospital) costs 11 of both HLA-identical sibling and unrelated donor SCT in a retrospective study, in patients treated between 1994 and 1999. The cost analysis was based on data from patients with acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), which are amongst the diagnostic categories for which SCT is currently most frequently used.
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Patients and methods
This cost analysis was performed by following two complementary methods. First, the usual method (multiplying the medical consumption units used by the patients (see P&M-1, below) by the unit costs of each of the items (see P& M-2) that can be distinguished within this consumption) was applied. However, a structural program for allogeneic transplants brings along costs that are not expressed within the registration of the medical consumption of patients (see P&M-3 to P&M-10). The costs of these items were identified by documents from the financial departments of the hospitals, and by expert opinion.
P&M-1 Patients
In four Dutch hospitals performing allogeneic stem cell transplants (University Medical Centres of Utrecht, Rotterdam, Nijmegen and Leiden), a random selection was made from patients with acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL) who had received a stem cell graft harvested from the bone marrow of an HLAidentical sibling (BMT), or a stem cell graft harvested from the peripheral blood of an HLA-identical sibling (PBSCT), or a stem cell graft from the bone marrow or peripheral blood of a voluntary matched unrelated donor (MUD). The transplants were performed between 1994 and 1999. We aimed to reach a 2-year follow-up, in which five phases were identified: (1) Pretransplantation: screening of the patient's eligibility to undergo allogeneic SCT; (2) Transplantation: starting with the first day of hospitalisation for the transplant procedure until the first discharge after the transplant procedure; (3) Follow-up phase 1: from the first discharge after the transplant procedure until 6 months after transplant date; (4) Follow-up phase 2: 6-12 months after transplantation date; (5) Follow-up phase 3: 12-24 months after transplantation date.
Irrespective of disease state, the aim was to follow all patients until 24 months after the transplant date or until the day they died, if earlier.
One phase was identified for the HLA-identical sibling donors: (1) Harvesting: from the first hospital visit preceding the harvesting to the final visit thereafter.
Within these phases, medical consumption items used by the patients and HLA-identical sibling donors were recorded, by using data from the hospital information systems and patient charts. The institutional perspective 13 was taken, as this analysis was designed to be a basis for determining a hospital budget.
P&M-2 Unit costs
In contrast to charges, unit costs are the best estimators of the theoretically exact opportunity costs. 13 Therefore, we determined average unit costs (Table 1) for the most important cost items that appeared from an inventory of medical consumption, reflecting real resource use, including an increase for overhead costs. 11, 14 Valuation of resources and overhead costs was based on financial data from two of the four hospitals (1998 level, 1 Euro = 2.20371 Dutch Guilders).
All unit costs excluded costs of the haematologists, because their costs were determined separately (see P&M-10). The unit cost of an isolation hospital day (Table 1) reflected the high nursing intensity for patients who have just received an allograft. Within the 'transplantation phase', all hospital days were multiplied by this unit cost. The hospital days in all other phases were multiplied by the unit cost of a regular hospital day, reflecting normal nursing intensity. Costs of parenteral nutrition were calculated separately. The unit cost of day care treatment was particularly based on the staff (excluding haematologist) and resources required for administrating blood components or performing phereses. The unit cost of an outpatient visit was based on the staff and resources required for a regular follow-up visit.
Diagnostic tests and other procedures were multiplied by Dutch tariffs, as these are proper approximations of the actual unit costs.
14 Costs of medication were based on Dutch 1998 wholesale prices. 15 
P&M-3 Pretransplantation screening
The transplantation process started with patient screening. Its costs were calculated on the basis of protocol schedules ( Table 2 ). The HLA was typed twice: one full test and one confirmatory test. Full HLA-typing included typing for HLA-ABC and HLA-DR(DQ) by serological and molecular methods. Confirmatory HLA-typing included determination of HLA-ABC and HLA-DR(DQ) by molecular methods.
P&M-4 Family HLA-typing (HLA-identical sibling transplant only)
Before an HLA-identical sibling transplant was performed (BMT or PBSCT), an average of four family members had been fully HLA typed, of whom one was finally selected as the stem cell donor. In Results, the HLA typing costs of the three rejected family members will be accounted for in the 'donor table' (Table 5) .
Typing costs of the selected donor (including a confirmatory HLA test) will be reflected in the 'donor table' (Table 5) .
P&M-5 Stem cell harvesting from HLA-identical siblings
In cases of an HLA-identical sibling transplant, the choice Table 2 Pretransplantation screening (unit costs in Euro) for harvesting stem cells from either the bone marrow (BM) or the peripheral blood (PB) is made by the donor.
Screening components Costs
BM stem cell harvesting:
Harvesting stem cells from BM was performed in one session in the operating theatre under general or local anaesthesia. Costs of the 2.5-h use of the theatre (including theatre personnel, equipment, cleaning, housing, and overheads) were 840 (including 274 overhead costs). It further required 2 h from two nurses, 0.5 h from an anaesthetist, and 2.5 h from an anaesthetic assistant. Their cumulative costs were 260. Material costs were 76. The total costs of BM stem cell harvesting were therefore 1176. Costs of two haematologists involved have not been calculated here, because their costs were calculated separately (P&M-10).
PB stem cell harvesting:
Harvesting stem cells from PB was performed at the day care centre in two sessions. The unit cost of day care treatment was therefore calculated twice ( 274). Nursing costs (5.5 h per harvesting) were 315. In total, the costs of PB stem cell harvesting added to 1209 (of which 371 was material costs, 56 equipment costs, and 193 overhead costs).
Bone Marrow Transplantation
P&M-6 Donor costs for unrelated transplants
The costs for searching for an unrelated allograft consisted of five parts: Family HLA-typing (P&M-6A), Requesting donor blood samples (P&M-6B), Sample typing (P&M-6C), Requesting the donor graft (P&M-6D), Europdonor costs (P&M-6E). In the results section, the costs of these parts are presented in Table 5 . About 45% of all patients for whom an unrelated allograft had been searched finally underwent transplantation. Sometimes no donor could be found (20%) or the donor was found when the patient's condition had deteriorated too much for transplantation (35%). However, for these 55% of all patients, search activities (P&M-6A to P&M-6C) were also undertaken. To give account for their costs, an increase of 122% (55/45) was applied to the costs of patients who underwent transplantation.
P&M-6A Family HLA typing
Although no HLA-identical sibling was found, the search for an HLA identical graft had been started initially on four family members (on average) of the patient. They were fully HLA typed (for costs see P&M-3). Also, in 15% of all cases, an average of six cousins were fully HLA typed. The costs added up to 3082. Account was given for the 55% of all MUD patients who did not undergo transplantation. This resulted in an increase of 3760 (122% of 3082) per transplanted patient. The total costs of family HLA typing therefore added up to 6842.
P&M-6B Requesting blood samples
The search for an unrelated HLA identical donor was started in the Bone Marrow Donors Worldwide system. On average, blood samples of six potential donors were requested, but only four requests were fulfilled (generally due to withdrawals of formerly potential donors). The charges for these samples are highly dependent on the country delivering the samples. We determined an average weighted charge of 620 per sample, based on the national registry specific charges and the percentage of samples originating from these countries. The costs of the four samples were therefore 2480. Applying the 122% rise for the patients who did not undergo transplantation led to total costs of 5506 per transplanted patient.
P&M-6C Sample typing
HLA retyping of each of the four samples was performed in the Dutch hospitals, consisting of a medium/low resolution HLA class I test and a high resolution test for DRB1/DQB, costing 390 per sample ( 1561)
P&M-6D Requesting donor graft
Again, the costs of the selected donor graft were highly dependent on country of origin. We determined an average weighted charge of 15 971 per graft (which generally contained stem cells harvested from bone marrow) on the basis of the country-specific charges and the percentage of grafts originating from these countries.
P&M-6E Europdonor intermediation
The average charges of the Europdonor Foundation, which coordinates the logistic procedures of requesting the samples and grafts for all Dutch transplant centres amounted to 1929 per transplanted patient.
P&M-7 CD34 selection or T cell depletion
When the stem cells had been collected (regardless of origin, ie related or unrelated), they all underwent CD34 selection or T cell depletion. For this calculation, we assessed them as identical procedures, as the required materials and equipment are comparable. These costs have been based on inventories from the participating hospitals. On average, the procedure amounted to 4592, consisting of reagents ( 2042), a large tubing set ( 1089), EDTA ( 100) and quality control tests ( 1361). The quality control tests included a FACS analysis (CD3, 4, 8, 19 , 34, 56), haematopoietic progenitor tests, sterility tests and freezing/storing reference vials (see Results, Table 5 ).
P&M-8 Donor lymphocyte infusion (DLI)
Patients sometimes needed one or more additional infusions with lymphocytes from the original stem cell donor to achieve complete remission. On average, one DLI was required in 50% of the transplanted patients. The additional costs of DLI depended on the origin of the stem cells (P&M-8A/8B). These costs are presented in the follow-up table (Table 6 ) of the Results section, as a DLI was mostly required in the follow-up phase 1.
P&M-8A DLI following HLA-identical sibling transplant
When DLI following HLA-identical sibling transplantation was done, the original donor was requested to visit the outpatient clinic (costs of an outpatient visit: 64). Additional tests were performed: haematological counts, white blood cell counts and differential counts ( 12) , chemistry tests (Na, K, Cl, Ca, P, HCO3, Creat, Bili, AF, gGT, SGOT, SGPT, LDH: 37), virus serology (HBsAg, HBcAg, CMV, EBV, VZV, HSV, HIV, Toxoplasmosis: 85). The use of materials, equipment and the staff required for the phereses was similar to that for the PB stem cell harvesting with the exception that lymphocytes pheresis was performed in one day care session only. Harvesting costs were therefore 1072. The harvested lymphocytes were processed at the stem cell laboratory, costing 753. The total DLI costs therefore added up to 2023. As DLIs were used in 50% of patients on average, half of this amount will be accounted for in the Results section (Table 6) .
P&M-8B DLI following unrelated transplantation
Charges for additional lymphocytes from the original unrelated stem cell donor consisted of the request for those lymphocytes and courier costs. Lymphocytes of European origin cost 4538 on average, of which 1134 was courier costs. Lymphocytes from other parts of the world cost 9076 on average, of which 2269 was courier costs. Two out of three requested unrelated lymphocytes came from European donors, which resulted in average DLI costs of 6051. Lymphocytes were processed at the stem cell laboratory in the Dutch transplant centre, costing 753. In total, the costs added up to 6804, of which 50% will be accounted for ( 3402) in the Results section (Table 6 ), for the above-mentioned reason.
P&M-9 Total body irradiation (TBI)
The conditioning regimen preceding transplantation consisted of cyclophosphamide (accounted for in costs of cytostatics; Results, Table 4 ) and TBI. The TBI procedure started with an outpatient visit to the radiotherapy department (at 64). The radiotherapist spent 70 min with each patient before the TBI and 35 min thereafter (costing 135). Laboratory personnel spent 355 min and 280 min, respectively (costing 303). Eighty minutes were required from administration staff ( 38). Debits for the accelerator, the simulator and the radiotherapy chair were 486, 36 and 69 per TBI. Exploitation costs amounted to 233. Costs of housing and overheads were 77 per TBI. In total, TBI costs summed up to 1441.
P&M-10 Transplantation program personnel
The personnel required to run a structured transplant (set at 35 transplants per year) program is reported in Table 3 . Note that the Table does Table  1 ) to give account for the difference between isolation hospital days and regular hospital days.
Total costs resulting from multiplying full-time equivalents (FTEs) of personnel in Table 3 by total employer costs (including wages, bonuses for irregular working hours and social premiums) added up to 929 001. If this amount is distributed over an average of 35 transplant patients per year, the costs would be 26 543. In the Results, these costs are presented in the final table (Table 7) .
Results
Patients
Data from 97 patients (45 male, 52 female; 66 AML, 31 ALL) were studied, of whom 47 had undergone sibling BMT, 29 MUD transplantation, 21 sibling PBSCT between 
Costs
Transplantation phase: The average costs per patient during the transplant phase (from the start of the high-dose conditioning regimen until first discharge after transplantation) are reported in Table 4 . The costs of the pretransplant screening (which had been specified in Table  2 ) have been accounted for in this phase. A specification of donor costs is presented in Table 5 . Costs of the haematology isolation hospital days are based on the average durations of hospitalisation during this phase: 39.74 (BMT), 43.10 (MUD) and 43.33 (PBSCT). In total, costs during the transplantation phase (including pretransplantation screening costs and donor costs) were 42 129 (BMT), 84 948 (MUD), and 45 734 (PBSCT). It should be noted that these costs do not include the costs of the transplantation personnel, as these will be reflected only in the final table (Table 7) . Table 6 presents the average costs during the follow-up phases, per patient alive (the percentage of patients alive within each of the phases is shown in Table  7 ). Only in the final table (Table 7) , will account be given to the fact that patients die during the follow-up. Again, Table 6 does not include costs of transplantation personnel; these have only been accounted for in Table 7 .
Follow-up phases:
In follow-up phase 1, the patients were hospitalised for 19.43 (BMT), 28.19 (MUD) and 13.20 days (PBSCT) on average. They visited the outpatient clinic 22.45 (BMT), 19 .00 (MUD) and 19.58 times (PBSCT) on average.
During follow-up phase 2 (6-12 months after transplantation), patients were hospitalised for 12.79 Table 4 Average costs per patient (Euro) during the transplantation phase (from start of high-dose conditioning regimen up to first discharge after the transplantation)
Cost component BMT MUD PBSCT
Pretransplantation screening (see Table 2 ) 2342 2342 2342 Donor costs (see Table 5 Note: Costs of the pretransplantation screening, donor costs and TBI costs have been specified in Tables 2, 5 and P&M-9, respectively. Table 7 also gives an impression of the costs of patients who were alive after 2 years follow-up, these were 103 509 (BMT), 173 587 (MUD) and 105 906 (PBSCT).
Discussion
We analysed the costs of 97 adult patients with AML or ALL who received a bone marrow (BMT) or peripheral blood stem cell graft (PBSCT) from an HLA-identical sibling or a graft from a voluntary matched unrelated donor (MUD). The average costs per transplanted patient were 98 334 (BMT), 151 754 (MUD), and 98 977 (PBSCT), including donor identification expenses, 2 years' follow-up and costs of patients who were not transplanted after they had been planned to receive an allograft. The vast majority of these costs was generated during hospitalisation for the transplant procedure. For MUD transplant, nearly one-third of these costs was spent on the search for a donor. Patients who were alive after 2 years had generated cumulative costs of 103 509 (BMT), 173 587 (MUD) and 105 906 (PBSCT). We have determined the average costs per patient and we assume we have calculated these adequately by assessing a large total number of patients. Nevertheless, it could be argued that a cost analysis should incorporate a sensitivity analysis to give account for uncertainty in the calculated average costs. 13 The reason for its omission was the difference in sources used to calculate the medical consumption of the patients. It was not possible to invest time in merging those different sources into one statistical database. In this analysis, the uncertainty in hospitalisation costs during the transplantation phase would be most important, as variation in this cost component may exert a major influence on the calculated average costs, due to the high unit cost of a hae-(MUD) and 43.33 (PBSCT). The 95% confidence intervals were 37.44-42.45 (BMT), 34.43-51.78 (MUD) and 35.50-51.17 (PBSCT), resulting in uncertainties of, respectively, 940 (1% of average total costs per patient), 3553 (2%) and 3205 (3%). As the sample sizes decreased due to a descending survival curve, variations in hospitalisation during the follow-up phases were somewhat wider, but these exerted less influence due to lower unit costs of the follow-up hospital days. Given these low variations, we estimate that the total uncertainty would not be higher than approximately 10%, particularly since the second major cost component (personnel costs) consists of fixed costs.
Few studies have so far reported costs of HLA-identical sibling SCT, [4] [5] [6] [7] [8] [9] and only one study has been published on costs of unrelated voluntary SCT 3 for a narrowly defined patient group, chronic phase CML. We have not attempted to compare the absolute costs reported, as there are too many possible biases and discrepancies. Some studies exclude certain cost items, unit costs are subject to a large variation between countries (particularly if they were based on charges), and price levels varied. Moreover, the followup durations assessed were not comparable between different publications, donor costs have not always been taken into account, and the 'state of technology' implicitly assessed may have been very different as most of the studies were based on patients treated in the 1980s (except studies described in Refs 3 and 9). Finally, except for one study, 3 the sample sizes on which the calculations were based, have generally been small (Ͻ43). We refer to Johnson et al 1 and Waters et al 2 for proper overviews of the costs calculated in different studies.
It is generally assumed that allogeneic PBSCT results in faster haematological recovery than allogeneic BMT, which was demonstrated by Bensinger in a retrospective analysis. 16 This faster recovery may lead to cost advantages of PBSCT over BMT, due to earlier discharge, fewer transfusions, and fewer antibiotics. These cost advantages have been confirmed several times in autologous transplants for lymphoma patients. [17] [18] [19] [20] [21] [22] In allogeneic transplants, such a cost advantage has been confirmed by Faucher et al. 9 Although this comparison was not the aim of our analysis, it is inconsistent that the costs of our PBSCT patients were found to be very similar to those of our BMT patients. Particularly in the transplantation phase, the former group was hospitalised somewhat longer. This difference may relate to the fact that the Dutch centres used PBSCT following T cell depletion, which had the potential advantage of reducing incidence and severity of post-transplantation graft-versus-host disease, but the disadvantage of losing some of the accelerated haematopoietic repopulation. In addition, we may coincidentally have selected a sample of PBSCT patients in a relatively poor condition.
An advantage of this analysis is that it provides an opportunity for defining the requirements for (setting up) a program for allogeneic transplants. A number of articles have already provided recommendations for the performance of SCT. [23] [24] [25] [26] Our analysis directly links the requirements of an infrastructural program for allogeneic transplants as drawn up by four experienced centres to their financial implications, and to numbers of full-time equivalents (FTEs).
Together with the studies of Lee et al 3 and Faucher et al, 9 our study is one of the very few on the costs of recent allogeneic transplants. Just as the earlier studies, it only considered direct medical (hospital) costs, but it comprises the largest sample of adult acute leukaemia patients assessed to date within a cost analysis, in which all essential components have been taken into account, including costs of donor identification, and a 2-year follow-up. A recommendation for future research would be to investigate the non-medical indirect costs, such as costs of lost production due to absence from work, as these costs may also be considerable in this young patient group.
